Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 215

1.

Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.

Sánchez-Guerrero J, Fragoso-Loyo HE, Neuwelt CM, Wallace DJ, Ginzler EM, Sherrer YR, McIlwain HH, Freeman PG, Aranow C, Petri MA, Deodhar AA, Blanton E, Manzi S, Kavanaugh A, Lisse JR, Ramsey-Goldman R, McKay JD, Kivitz AJ, Mease PJ, Winkler AE, Kahl LE, Lee AH, Furie RA, Strand CV, Lou L, Ahmed M, Quarles B, Schwartz KE.

J Rheumatol. 2008 Aug;35(8):1567-75. Epub 2008 Jul 15.

PMID:
18634158
3.

Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study.

Ettinger MP, Littlejohn TW, Schwartz SL, Weiss SR, McIlwain HH, Heymsfield SB, Bray GA, Roberts WG, Heyman ER, Stambler N, Heshka S, Vicary C, Guler HP.

JAMA. 2003 Apr 9;289(14):1826-32.

PMID:
12684362
4.

Glucocorticoid-induced osteoporosis: pathogenesis, diagnosis, and management.

McIlwain HH.

Prev Med. 2003 Feb;36(2):243-9. Review.

PMID:
12591000
5.

A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.

Matsumoto AK, Melian A, Mandel DR, McIlwain HH, Borenstein D, Zhao PL, Lines CR, Gertz BJ, Curtis S; Etoricoxib Rheumatoid Arthritis Study Group.

J Rheumatol. 2002 Aug;29(8):1623-30.

PMID:
12180720
6.

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.

Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A.

Arthritis Rheum. 2001 Jan;44(1):202-11.

7.

An estradiol matrix transdermal system for the prevention of postmenopausal bone loss.

McKeever C, McIlwain H, Greenwald M, Gupta N, Jayawardene S, Huels G, Roberts M.

Clin Ther. 2000 Jul;22(7):845-57.

PMID:
10945511
8.

Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.

Ehrich EW, Schnitzer TJ, McIlwain H, Levy R, Wolfe F, Weisman M, Zeng Q, Morrison B, Bolognese J, Seidenberg B, Gertz BJ.

J Rheumatol. 1999 Nov;26(11):2438-47.

PMID:
10555907
9.

An open-label extension study of alendronate treatment in elderly women with osteoporosis.

Downs RW Jr, Bone HG, McIlwain H, Baker MZ, Yates AJ, Lombardi A, Krupa D, Harning R.

Calcif Tissue Int. 1999 Jun;64(6):463-9.

PMID:
10341016
10.

Flare during drug withdrawal as a method to support efficacy in rheumatoid arthritis: amiprilose hydrochloride as an example in a double blind, randomized study.

Caldwell JR, Furst DE, Smith AL, Clark JA, Bonebrake RA, Gruhn WB, McIlwain HH, Logue CM.

J Rheumatol. 1998 Jan;25(1):30-5.

PMID:
9458199
11.

Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.

Siris E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, Lyles K, McIlwain H, Murphy WA Jr, Reda C, Rude R, Seton M, Tiegs R, Thompson D, Tucci JR, Yates AJ, Zimering M.

J Clin Endocrinol Metab. 1996 Mar;81(3):961-7.

PMID:
8772558
12.

Contributions to neurochemical knowledge considered ecologically.

McIlwain H.

Mol Chem Neuropathol. 1992 Jun;16(3):289-302.

PMID:
1418221
13.
14.

Biochemistry and neurochemistry in the 1800s: their origins in comparative animal chemistry.

McIlwain H.

Essays Biochem. 1990;25:197-224. No abstract available.

PMID:
2199192
15.

Intra-articular orgotein in osteoarthritis of the knee: a placebo-controlled efficacy, safety, and dosage comparison.

McIlwain H, Silverfield JC, Cheatum DE, Poiley J, Taborn J, Ignaczak T, Multz CV.

Am J Med. 1989 Sep;87(3):295-300.

PMID:
2773967
16.

Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub).

Levine LR, Enas GG, Thompson WL, Byyny RL, Dauer AD, Kirby RW, Kreindler TG, Levy B, Lucas CP, McIlwain HH, et al.

Int J Obes. 1989;13(5):635-45.

PMID:
2583918
17.

Piroxicam versus naproxen in the treatment of acute musculoskeletal disorders in athletes.

McIlwain HH, Platt RD.

Am J Med. 1988 May 20;84(5A):56-60.

PMID:
2454027
18.

Neurochemistry and related terms: their introduction and acceptance.

McIlwain H.

Neurochem Int. 1988;12(4):431-8.

PMID:
20501248
19.

Adenosine modifies colchicine-uptake into tissues from the mammalian brain.

McIlwain H, Dinsdale J.

Neurochem Int. 1987;10(2):237-43.

PMID:
20501076
20.
22.
23.

Assay-guided isolation of naturally-occurring neuroactive substances.

McIlwain H.

Psychol Med. 1985 Feb;15(1):15-26.

PMID:
3887447
24.
25.
26.

Neurochemistry and Sherrington's enchanted loom.

McIlwain H.

J R Soc Med. 1984 May;77(5):417-25. No abstract available.

27.
28.

Erythrocyte transketolase activity in the Wernicke-Korsakoff syndrome.

Leigh D, McBurney A, McIlwain H.

Br J Psychiatry. 1981 Aug;139:153-6.

PMID:
7306754
29.

Wernicke-Korsakoff syndrome in monozygotic twins: a biochemical peculiarity.

Leigh D, McBurney A, McIlwain H.

Br J Psychiatry. 1981 Aug;139:156-9.

PMID:
7197998
30.

The flow of thought and the flow of substance in the brain.

McIlwain H.

Biol Psychol. 1981 Mar-May;12(2-3):147-69.

PMID:
6174159
31.
33.
34.

Pursuing the actions of psychotropic drugs: receptor sites and endogenous cerebral programmes.

McIlwain H.

Psychol Med. 1980 Aug;10(3):399-402. No abstract available.

PMID:
6108586
35.

Adenosine-binding to cerebral preparations in interpretation of adenosine activation of adenosine 3':5'-cyclic monophosphate formation [proceedings].

Newman ME, De Lucia R, Patel J, McIlwain H.

Biochem Soc Trans. 1980 Feb;8(1):141-2. No abstract available.

PMID:
6245956
36.
37.

Limited plasmapheresis in rheumatoid arthritis with vasculitis.

Goldman JA, Casey HL, McIlwain H, Kirby J, Wilson CH Jr, Miller SB.

Arthritis Rheum. 1979 Oct;22(10):1146-50. No abstract available.

PMID:
39566
39.
40.

Synaptic mediators and the structuring of cerebral activity.

McIlwain H.

Prog Neurobiol. 1978;11(3-4):189-203. Review. No abstract available.

PMID:
85314
41.

Redistribution of adenine derivatives among subcellular fractions from guinea pig neocortical tissues, on incubation in vitro.

Barberis C, McIlwain H.

J Neurochem. 1977 Jul;29(1):77-81. No abstract available.

PMID:
886323
43.

Adenine mononucleotides and their metabolites liberated from and applied to isolated tissues of the mammalian brain.

Pull I, McIlwain H.

Neurochem Res. 1977 Apr;2(2):203-16. doi: 10.1007/BF00964097.

PMID:
24271953
44.
45.

Extended roles in the brain for second-messenger systems.

McIlwain H.

Neuroscience. 1977;2(3):357-72. Review. No abstract available.

PMID:
70763
46.

Translocation of neural modulators a second category of nerve signal.

McIlwain H.

Neurochem Res. 1976 Aug;1(4):351-68. doi: 10.1007/BF00966228.

PMID:
24271568
47.
48.

An extended messenger-role in the brain for cyclic AMP.

McIlwain H.

FEBS Lett. 1976 May 1;64(2):271-3. No abstract available.

50.

Supplemental Content

Loading ...
Support Center